ArticleCureus2026
Histopathological Outcomes of Thy3 Thyroid Nodules: Malignancy Risk in an Indeterminate Cytology Cohort.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn our centre, we observed a higher than nationally reported malignancy rate among indeterminate thyroid nodules. As a result, we adopted a practice of offering diagnostic hemithyroidectomy to patients with Thy3a cytology. This study aims to evaluate the malignancy rate of indeterminate thyroid nodules following this change in practice.
methodsWe conducted a retrospective study of patients with Thy3 thyroid nodules who underwent thyroidectomy at our centre between January 2022 and December 2023. We recorded and analysed patients' demographics, nodule size, and histopathological outcomes.
resultsDuring the study period, 262 thyroidectomies were performed, of which 136 (51.9%) had a pre-operative Thy3 cytology. The majority of patients were females (N=97, 71.3%), and the average age was 51.4 years. The overall malignancy rate was 24.3%. In the Thy3a group (N=109), the malignancy rate was 19.3%, and the nodule size in the benign group was larger (38.1mm versus 31.7mm). In the Thy3f group (N=27), the malignancy rate was 44.4%, and the nodule size did not differ significantly between the groups (24.7mm versus 25.2mm).
conclusionAlmost every second patient with Thy3f cytology and approximately one in five patients with Thy3a cytology were diagnosed with thyroid cancer. Given the significant variation between centres, we recommend that individual endocrine units assess their local malignancy rates to better inform discussions with patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.